Cytosorbents (CTSO)
(Delayed Data from NSDQ)
$1.13 USD
+0.01 (0.89%)
Updated Oct 17, 2024 04:00 PM ET
After-Market: $1.13 0.00 (0.00%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1.13 USD
+0.01 (0.89%)
Updated Oct 17, 2024 04:00 PM ET
After-Market: $1.13 0.00 (0.00%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
CytoSorbents (CTSO) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
CytoSorbents (CTSO) delivered earnings and revenue surprises of -75% and 9.78%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
CytoSorbents (CTSO) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
CytoSorbents (CTSO) delivered earnings and revenue surprises of -78.57% and 11.15%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Abbott (ABT) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
Abbott (ABT) delivered earnings and revenue surprises of 31.19% and 8.67%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?